

EDITORIAL  
FRAILITY, COMORBIDITY, AND COPD

E. CHARBEK<sup>1</sup>, J.R. ESPIRITU<sup>1</sup>, R. NAYAK<sup>1</sup>, J.E. MORLEY<sup>2</sup>


1. Division of Pulmonary, Critical Care, and Sleep Medicine, Saint Louis University School of Medicine, St. Louis, Missouri; 2. Division of Geriatric Medicine, Saint Louis University School of Medicine, St. Louis, Missouri, USA. Corresponding author: John E. Morley, MB, BCh, Division of Geriatric Medicine, Saint Louis University School of Medicine, 1402 S. Grand Blvd., M238, St. Louis, MO, USA 63104, Email: john.morley@health.slu.edu

Chronic Obstructive Pulmonary Disease (COPD) is the third most common cause of mortality in the U.S.A. (1). The Global Initiative for Chronic Obstructive Lung Disease (GOLD) defines COPD as “a common, preventable and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases” (2). COPD can directly lead to or accelerate co-morbidities through hypoxia, dyspnea, polycythemia, pulmonary hypertension, and decreased activity (Figure 1). Older age and decreased cognition may lead to incorrect inhaler techniques (3). Persons with COPD have an average of 7 co-morbidities compared to 3 for other persons (4). The existence of comorbidities is strongly related to COPD exacerbations and symptoms (5). The Body Mass Index, Airflow Obstruction, Dyspnea and Exercise Capacity (BODE) Index is a simple index predicting the risk of death in patients with COPD (6). Using the Frailty Index, a co-morbidity index of multiple morbidities, 56.6% of persons with COPD were found to be frail in the National Health and Nutrition Examination Survey (NHANES) (7). Not surprisingly, many of these persons had some functional disability. Patients with COPD are more likely to be frail than other patients (8). A meta-analysis found that patients with COPD were twice as likely to be frail (9).

Physical frailty has been defined as “a medical syndrome with multiple causes and contributor that is characterized by diminished strength, endurance, and reduced physiologic function that increases an individual’s vulnerability for developing increased dependency and/or death” (10). It should

be distinguished from disability. The concept of a physical frailty phenotype was originally described by Fried et al (11). Their criteria were unintentional weight loss, self-reported exhaustion, weakness (grip strength), slow walking speed and low physical activity using the Fried criteria in persons with COPD, there was an increase in frailty with persons with a higher GOLD score (12). Table 1 provides the prevalence of the physical frailty phenotype in persons with COPD (12-17). In frail persons undergoing pulmonary rehabilitation 61.3% were no longer frail and had better exercise performance following pulmonary rehabilitation.

Figure 1  
The COPD “Comorbidome”



FRAIL (fatigue, resistance, ambulation, illnesses and loss of weight) is a rapid screen for frailty that has been shown to identify persons at risk for functional deterioration,


Table 1  
Prevalence of Physical Frailty Phenotype in COPD

Author	Year	n	Prevalence	Comments
Galizia et al (13)	2011	489	49%	Increased mortality
Singer et al (14)	2015	395	28%	Increased disability and mortality
Mittal et al (15)	2015	30	17%	Improved with pulmonary rehabilitation
Valenza et al (16)	2016	212	63%	-
Lahousse et al (17)	2016	402	5%	Increased mortality
Maddocks et al (12)	2016	816	26%	Increased mortality
Improved with pulmonary rehabilitation				

hospitalization and mortality (18-23). Limpawattana et al (24) found that using the FRAIL scale frailty was present in 6.6% and prefrailty 41.3% in persons with COPD. Fatigue was the most common component of the FRAIL scale present in persons with COPD. In persons with COPD who were assessed by the Edmonton Frail Scale, severely frail patients were more likely to be readmitted to hospital within 90 days than were nonfrail patients (25). Using the Kihon index to determine frailty in persons with COPD, frailty was found to be strongly related to patient reported outcomes but not to lung function measurements (26).

**Figure 2**

Mechanisms of Sarcopenia in Persons with COPD



Sarcopenia is defined as low physical function in persons with a low muscle mass (27-30). Jones et al (31) reported that sarcopenia was present in 15% of COPD patients. It was associated with less functional performance exercise capacity and health status. In the Rotterdam study, sarcopenia was present in 26.9% of COPD patients (32). Both of these studies utilized the European Working Group on Sarcopenia in Older People definition to make the diagnosis. Using the Asian Working Group for Sarcopenia definition, the prevalence for sarcopenia in COPD in Asia was 24% (33). In Brazil the prevalence of sarcopenia in COPD was 24% (34). Another study in Brazil using the Foundation of the National Institute of Health definition (FNIH) found a prevalence of sarcopenia in COPD was 12.4% (35). Patients with sarcopenia had a worse outcome. SARC-F is a rapid screen for sarcopenia which has been demonstrated to be valid and predict declining function and mortality (36-39).

There are numerous causes of sarcopenia, many of which are very common in COPD (40-42). These include weight loss (43), low testosterone (44), inflammation (45), all of which are more common in COPD than in the average patient. Hypercapnia leads to an increase in protein catabolism by activating E3-ubiquitin ligase and atrogen-1 (46). Myostatin inhibits muscle growth (47). Myostatin levels are elevated in cor pulmonale secondary to COPD (7, 48). COPD is associated with systemic inflammation which leads to oxidative damage of

muscle (49). Oxidative damage can lead to decreased function of titin (50). All these changes lead to a relative decrease in type I fibers compared to type II fibers (51). The mechanisms of sarcopenia in patients with COPD are illustrated in Figure 2.

Persons with COPD develop anorexia because they become dyspneic when eating due to hypoxia related to the thermic energy of eating (52-55). A Cochrane review by Ferreira IM et al. found that nutritional supplementation increases respiratory muscle strength, improves health related quality of life, and increase BMI and 6-minute walk distance in malnourished patients (56). Depression is also more common in COPD and it also leads to anorexia and weight loss (57-59). For these reasons all persons with COPD should be screened for anorexia using the Simplified Nutrition Appetite Questionnaire (SNAQ) (60-63). The inflammation associated with COPD further leads to muscle loss resulting in severe cachexia especially in persons with emphysema (64, 65).

The combination of comorbidities and geriatric syndromes requires an integrated disease management approach for COPD (66). Alvin L. Barach (67) and Thomas Petty (68) were the first to suggest that exercise was a key component of pulmonary rehabilitation. It has been shown that exercise together with protein supplementation is the most efficacious management for COPD (69-72). An exercise intervention prescribed in 58 frail older patients after hospital admission for acute COPD exacerbation in improved muscle strength, balance, and exacerbation (73, 74). For this reason, replacement with 1,000 IU of vitamin D daily may be reasonable in patients with COPD (73).

Palliative care is appropriate for persons with end-stage COPD (75). It is defined by the World Health Organization as "An approach that improves the quality of life of patients and their families facing the problems associated with life threatening illnesses." Table 2 provides appropriate criteria for being considered for palliative care. However, there is only a limited amount of evidence supporting the use of palliative care in COPD patients (76). There is need for a multicenter study to examine the role of palliative care in end-stage COPD patients.

## References

1. Cortopassi F, Gurung P, Pinto-Plata V. Chronic obstructive pulmonary disease in elderly patients. *Clin Geriatr Med* 2017;33:539-552.
2. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. *Am J Respir Crit Care Med* 2017;195:557-582.
3. Barbara S, Kritikos V, Bosnic-Anticevich S. Inhaler technique: Does age matter? *Eur Respir Review* 2017;26(146):170055.
4. Baty F, Putora PM, Isenring B, et al. Comorbidities and burden of COPD: A population based case-control study. *PLoS One* 2013;8:e63285. Doi: 10.1371/journal.pne.0063285.
5. Kahnert K, Alter P, Young D, et al. The revised GOLD 2017 COPD categorization in relation to comorbidities. *Respir Med* 2018;134:79-85.
6. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. *N Engl J Med* 2004;350:1005-1012.
7. Blodgett J, Theou O, Kirkland S, et al. Frailty in NHANES: Comparing the frailty index and phenotype. *Arch Gerontol Geriatr* 2015;70:464-470.
8. Gale NS, Albarrati AM, Munnery MM, et al. Frailty: A global measure of the multisystem impact of COPD. *Chron Respir Dis* 2018 Jan 1:1479972315763. DOI: 10.1177/1479972317752763. [Epub ahead of print].

# *FRAILITY, COMORBIDITY, AND COPD*

9. Marengoni A, Vetrano DL, Manes-Gravina E, et al. The relationship between chronic obstructive pulmonary disease and frailty: A systematic review and meta-analysis of observational studies. *Chest* 2018; Feb 22. Doi: 10.1016/j.chest.2018.02.014 [Epub ahead of print].
10. Morley JE, Vellas B, van Kan GA, et al. Frailty consensus: A call to action. *J Am Med Dir Assoc* 2013;14:392-397.
11. Fried LP, Tangen CM, Walston J, et al; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: Evidence for a phenotype. *J Gerontol A Biol Sci Med Sci* 2001;56:M146-M156.
12. Maddocks M, Kon SS, Canavan JL, et al. Physical frailty and pulmonary rehabilitation in COPD: A prospective cohort study. *Thorax* 2016;71:988-995.
13. Galizia G, Cacciatore F, Testa G, et al. Role of clinical frailty on long-term mortality of elderly subjects with and without chronic obstructive pulmonary disease. *Aging Clin Exp Res* 2011;23:118-125.
14. Singer JP, Diamond JM, Gries CJ, et al. Frailty phenotypes, disability, and outcomes in adult candidates for lung transplantation. *Am J Respir Crit Care Med* 2015;194:1325-1334.
15. Mittal N, Raj R, Islam E. Pulmonary rehabilitation improves frailty and gait speed in some ambulatory patients with chronic lung diseases. *SWRCCC* 2015;3:2-10.
16. Valenza MC, Torres-Sanchez I, Cabrera-Martos I, et al. Physical activity as a predictor of absence of frailty in subjects with stable COPD and COPD exacerbation. *Respir Care* 2016;61:212-219.
17. Lehouste L, Ziere G, Verlinden VJ, et al. Risk of frailty in elderly with COPD: A population-based study. *J Gerontol A Biol Sci Med Sci* 2015;71:689-695.
18. Woo J, Leung J, Morley JE. Comparison of frailty indicators based on clinical phenotype and the multiple deficit approach in predicting mortality and physical limitation. *J Am Geriatr Soc* 2012;60:1478-1486.
19. Morley JE, Malmstrom TK, Miller DK. A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans. *J Nutr Health Aging* 2012;16:601-608.
20. Malmstrom TK, Miller DK, Morley JE. A comparison of four frailty models. *J Am Geriatr Soc* 2014;62:721-726.
21. Fougere B, Morley JE. Editorial: Weight loss is a major cause of frailty. *J Nutr Health Aging* 2017;21:933-935.
22. Dent E, Lien C, Lim WS, et al. The Asia-Pacific Clinical practice guidelines for the management of frailty. *J Am Med Dir Assoc* 2017;18:564-575.
23. Morley JE. Developing novel therapeutic approaches to frailty. *Curr Pharm Des* 2009;15:3384-3395.
24. Limpawattana P, Putraveepong S, Inthasuwat P, et al. Frailty syndrome in ambulatory patients with COPD. *Int J Chron Obstruct Pulmon Dis* 2017;12:1193-1198.
25. Bernabeu-Mora R, Garcia-Guillamon G, Valera-Novella E, et al. Frailty is a predictive factor of readmission within 90 days of hospitalization for acute exacerbations of chronic obstructive pulmonary disease: A longitudinal study. *Ther Adv Respir Dis* 2017;11:383-392.
26. Kusunose M, Oga T, Nakamura S, et al. Frailty and patient-reported outcomes in subjects with chronic obstructive pulmonary disease: Are they independent entities? *BMJ Open Respir Res* 2017;4:e000196. Doi: 10.1136/bmjresp-2017-000196. eCollection 2017.
27. Morley JE. Hormones and sarcopenia. *Curr Pharm Des* 2017;23:4484-4492.
28. Morley JE, Anker SD. Myopenia and Precision(P4) medicine *J Cachexia Sarcopenia Muscle* 2017; 857-863.
29. Morley JE, Malmstrom TK, Rodriguez-Manas L, Sinclair AJ. Frailty, sarcopenia and diabetes. *J Am Med Dir Assoc* 2014;15:853-859.
30. Anker SD, Morley JE, von Haehling S. Welcome to the ICD-10 code for sarcopenia. *J Cachexia Sarcopenia Muscle* 2016;7:512-514.
31. Jones SE, Maddocks M, Kon SS, et al. Sarcopenia in COPD: Prevalence, clinical correlates and response to pulmonary rehabilitation. *Thorax* 2015;70:213-218.
32. Trajanoska K, Schoufour JD, Darweesh SK, et al. Sarcopenia and its clinical correlates in the general population: The Rotterdam study. *J Bone Miner Res* 2018;Mar 4. DOI: 10.1002/jbmr.2416 [Epub ahead of print].
33. Limpawattana P, Inthasuwat P, Putraveepong S, et al. Sarcopenia in chronic obstructive pulmonary disease: A study of prevalence and associated factors in the Southeast Asian population. *Chron Respir Dis* 2017 Jan 1:1479972317743759. Doi: 10.1177/1479972317743759 [Epub ahead of print].
34. de Blasio F, Di Gregorio A, de Blasio F, et al. Malnutrition and sarcopenia assessment in patients with chronic obstructive pulmonary disease according to international diagnostic criteria, and evaluation of raw BIA variables. *Respir Med* 2018;134:1-5.
35. Costa TM, Costa FM, Moreira CA, et al. Sarcopenia in COPD: Relationship with COPD severity and prognosis. *J Bras Pneumol* 2015;41:415-421.
36. Malmstrom TK, Miller DK, Simonsick EM, et al. SARC-F: A symptom score to predict persons with sarcopenia at risk for poor functional outcomes. *J Cachexia Sarcopenia Muscle* 2016;7:28-36.
37. Woo J, Leung J, Morley JE. Validating the SARC-F: A suitable community screening tool for sarcopenia? *J Am Med Dir Assoc* 2014;15:630-634.
38. Tanaka S, Kamiya K, Hamazaki N, et al. Utility of SARC-F for assessing physical function in elderly patients with cardiovascular disease. *J Am Med Dir Assoc* 2017;18:176-181.
39. Liccini A, Malmstrom TK. Frailty and sarcopenia as predictors of adverse health outcomes in persons with diabetes mellitus. *J Am Med Dir Assoc* 2016;17:846-851.
40. Morley JE. Pharmacologic options for the treatment of sarcopenia. *Calcif Tissue Int* 2016;98:319-333.
41. Morley JE. Sarcopenia in the elderly. *Fam Pract* 2012;29 Suppl 1:i44-i48.
42. Morley JE. Sarcopenia: Diagnosis and treatment, *J Nutr Health Aging* 2008;12:452-456.
43. Morley JE. Weight loss in older persons: New therapeutic approaches. *Curr Pharm Des* 2007;13:3637-3647.
44. Baumgartner RN, Waters DL, Gallagher D, et al. Predictors of skeletal muscle mass in elderly men and women. *Mech Ageing Dev* 1999;107:123-136.
45. McKee A, Morley JE, Matsumoto AM, Vinik A. Sarcopenia: An endocrine disorder? *Endocr Pract* 2017;23:1140-1149.
46. Jaitovich A, Angulo M, Lecuona E, et al. High CO2 levels cause skeletal muscle atrophy via AMP-activated kinase (AMPK), FoxO3aprotein, and muscle-specific ring finger protein 1 (MuRF1). *J Biol Chem* 2015;290:9183-9194.
47. Ju CR, Zhang JH, Chen M, Chen RC. Plasma myostatin levels are related to the extent of right ventricular dysfunction in exacerbation of chronic obstructive pulmonary disease. *Biomarkers* 2017;22:246-252.
48. Zhou X, Yi D, Wu Y, et al. Expression of diaphragmatic myostatin and correlation with apoptosis in rats with chronic obstructive pulmonary disease. *Exp Ther Med* 2018;15:2295-2300.
49. Boukhenouna S, Wilson MA, Bahmed K, Kosmider B. Reactive oxygen species in chronic obstructive pulmonary disease. *Oxid Med Cell Longev* 2018 Feb 11;2018:5730395. Doi: 10.1155/2018/5730395 [Epub ahead of print].
50. Ottenheim CA, Heunks LM, Hafmans T, et al. Titin and diaphragm dysfunction in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2006;173:527-534.
51. Van de Boel C, Gosker HR, van den Borst B, et al. Muscle quality is more impaired in sarcopenic patients with chronic obstructive pulmonary disease. *J Am Med Dir Assoc* 2016;17:415-420.
52. Morley JE. Anorexia of ageing: A key component in the pathogenesis of both sarcopenia and cachexia. *J Cachexia Sarcopenia Muscle* 2017;8:523-526.
53. Ezeoke CC, Morley JE. Pathophysiology of anorexia in the cancer cachexia syndrome. *J Cachexia Sarcopenia Muscle* 2015;6:287-302.
54. Morley JE. Pathophysiology of the anorexia of aging. *Curr Opin Clin Nutr Metab Care* 2013;16:27-32.
55. Wilson MM, Morley JE. Invited review: Aging and energy balance. *J Appl Physiol* (1985) 2003;95:1728-1736.
56. Ferreira IM, Brooks D, White J, Goldstein R. Nutritional supplementation for stable chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews* 2012, Issue 12. Art. No.: CD000998. DOI: 10.1002/14651858.CD000998.pub3
57. Yohannes AM, Kaplan A, Hanania NA. COPD in primary care: Key considerations for optimized management: Anxiety and depression in chronic obstructive pulmonary disease: Recognition and management. *J Fam Pract* 2018;67 (2 Suppl):S11-S18.
58. Feng L, Lim WS, Chong MS, et al. Depressive symptoms increase the risk of mild neurocognitive disorders among elderly Chinese. *J Nutr Health Aging* 2017;21:161-164.
59. Morley JE. Depression in nursing home residents. *J Am Med Dir Assoc* 2010;11:301-303.
60. Tokudome Y, Okumura K, Kumagai Y, et al. Development of the Japanese version of the council on nutrition appetite questionnaire and its simplified versions, and evaluation of their reliability, validity, and reproducibility. *J Epidemiol* 2017;27:524-530.
61. Pilgrim AL, Baylis D, Jameson KA, et al. Measuring appetite with the Simplified Nutritional Appetite Questionnaire Identifies hospitalized older people at risk of worse health outcomes. *J Nutr Health Aging* 2016;20:3-7.
62. Rolland Y, Perrin A, Gardette V, et al. Screening older people at risk of malnutrition or malnourished using the Simplified Nutritional Appetite Questionnaire (SNAQ): A comparison with the Mini-Nutritional Assessment (MNA) tool. *J Am Med Dir Assoc* 2012;13:31-34.
63. Wilson MM, Thomas DR, Rubenstein LZ, et al. Appetite assessment: Simple appetite questionnaire predicts weight loss in community-dwelling adults and nursing home residents. *Am J Clin Nutr* 2005;82:1074-1081.
64. Sanders KJ, Kneppers AE, van de Boel C, et al. Cachexia in chronic obstructive pulmonary disease: New insights and therapeutic perspective. *J Cachexia Sarcopenia Muscle* 2016;7:5-22.
65. Morley JE, Thomas DR, Wilson MM. Cachexia, pathophysiology and clinical relevance. *Am J Clin Nutr* 2006;83:735-743.
66. Morley JE. Chronic obstructive pulmonary disease: A disease of older persons. *J Am Med Dir Assoc* 2014;15:151-153.
67. Barach AL. The rehabilitative program in pulmonary emphysema. *J Am Geriatr Soc* 1967;15:183-184.
68. Petty TL. Pulmonary rehabilitation of early COPD. COPD as a systemic disease. *Chest* 1994;105:1636-1637.
69. van Wetering CR, Hoogendoorn M, Broekhuizen R, et al. Efficacy and costs of nutritional rehabilitation in muscle-wasted patients with chronic obstructive

- pulmonary disease in a community-based setting: A prespecified subgroup analysis of the INTERCOM trial. *J Am Med Dir Assoc* 2010;11:179-187.
70. van de Bool C, Rutten EPA, van Helvoort A, et al. A randomized clinical trial investigating the efficacy of targeted nutrition as adjunct to exercise training in COPD. *J Cachexia Sarcopenia Muscle* 2017;8:748-758.
71. Stewart KF, Meis JJ, van de Bool C et al. Maintenance of a physically active lifestyle after pulmonary rehabilitation in patients with COPD: A qualitative study toward motivational factors. *J Am Med Dir Assoc* 2014;15:655-664.
72. Kopturk N, Baha A, Oh YM, et al. Vitamin D deficiency: What does it mean for chronic obstructive pulmonary disease (COPD)? A comprehensive review for pulmonologists. *Clin Respir J* 2018;12:382-397.
73. Morley JE. Vitamin D redux. *J Am Med Dir Assoc* 2009;10:591-592.
74. Torres-Sanchez I, et al. Effects of an exercise intervention in frail older patients with chronic obstructive pulmonary disease hospitalized due to an exacerbation: A randomized controlled trial. *COPD* 2017;14:37-42.
75. Cruz-Oliver DM, Little MO, Woo J, Morley JE. End-of-life care in low- and middle-income countries. *Bull World Health Organ* 2017;95:731. Doi: 10.2471/BLT.16.185199.
76. Higginson IJ, Finlay IG, Goodwin DM, et al. Is there evidence that palliative care teams alter end-of-life experiences of patients and their caregivers? *J Pain Symp Management* 2003;25:150-168.
41. Sinclair AJ, Abdelhafiz A, Dunning T, et al. An international position statement on the management of frailty in diabetes mellitus: Summary of recommendations 2017. *J Frailty Aging* 2018;7:10-20.
42. Sinclair A, Morley JE, Rodriguez-Manas L, et al. Diabetes mellitus in older people: Position statement of behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. *J Am Med Dir Assoc* 2012;13:497-502.
43. Morrison S, Simmons R, Colberg SR, et al. Supervised balance training and Wii Fit-based exercises lower falls risk in older adults with type 2 diabetes. *J Am Med Dir Assoc* 2018;19:185.e7-185.e13.
44. Cockayne S, Adamson J, Corbacho Martin B, et al. The REFORM study protocol: A cohort randomized controlled trial of a multifaceted podiatry intervention for the prevention of falls in older people. *BMJ Open* 2014;4(12):e006977.
45. Rodriguez-Sanz D, Tovaruela-Carrion N, Lopez-Lopez D, et al. Foot disorders in the elderly: A mini-review. *Dis Mon* 2018;64:64-91.
46. Donoghue OA, Setti A, O'Leary N, Kenny RA. Self-reported unsteadiness predicts fear of falling, activity. Restriction, falls, and disability. *J Am Med Dir Assoc* 2017;18:597-602.
47. Kim S, Kim M, Won CW. Validation of the Korean version of the SARC-F questionnaire to assess sarcopenia: Korean frailty and aging cohort study. *J Am Med Dir Assoc* 2018;19:40-45.e1.
48. Tanaka S, Kamiya K, Hamazaki N, et al. Utility of SARC-F for assessing physical function in elderly patients with cardiovascular disease. *J Am Med Dir Assoc* 2017;18:176-181.
49. Balogun S, Winzenberg T, Wills K, et al. Prospective associations of low muscle mass and function with 10-year falls risk, incident fracture and mortality in community-dwelling older adults. *J Nutr Health Aging* 2017;21:843-848.
50. Vlietstra L, Hendrickx W, Waters DL. Exercise interventions in healthy older adults with sarcopenia: A systematic review and meta-analysis. *Australas J Ageing* 2018;Apr 11. DOI: 10.1111/ajag.12521 [Epub ahead of print].
51. Papa EV, Dong X, Hassan M. Resistance training for activity limitations in older adults with skeletal muscle function deficits: A systematic review. *Clin Interv Aging* 2017;12:955-961.
52. Bauer JM, Verlaan S, Bautmans I, et al. Effects of a vitamin D and leucine-enriched whey protein nutritional supplement on measures of sarcopenia in older adults, the PROVIDE study: A randomized, double-blind, placebo-controlled trial. *J Am Med Dir Assoc* 2015;16:740-747.
53. Bauer J, Biolo G, Cederholm T, et al. Evidence-based recommendations for optimal dietary protein intake in older people: A position paper from the PROT-AGE study group. *J Am Med Dir Assoc* 2013;14:542-559.
54. Moncada LVV, Mire LG. Preventing falls in older persons. *Am Fam Physician* 2017;96:240-247.
55. Quigley P, Bulat T, Kurtzman E, et al. Fall prevention and injury protection for nursing home residents. *J Am Med Dir Assoc* 2010;11:284-293.
56. Arnold AC, Raj SR. Orthostatic hypotension: A practical approach to investigation and management. *Can J Cardiol* 2017;33:1725-1728.
57. Zhang R, Malmstrom TK. Implications of orthostatic hypotension in older persons with and without diabetes. *J Am Med Dir Assoc* 2017;18:84-85.
58. Iwanczyk L, Weintraub NT, Rubenstein LZ. Orthostatic hypotension in the nursing home setting. *J Am Med Dir Assoc* 2006;7:163-167.
59. Trahair LG, Horowitz M, Jones KL. Postprandial hypotension: A systematic review. *J Am Med Dir Assoc* 2014;15:394-409.
60. Pavelic A, Krbot Skorac M, Crnosija L, Habek M. Postprandial hypotension in neurological disorders; Systematic review and meta-analysis. *Clin Auton Res* 2017;27:263-271.
61. Lee A, Patrick P, Wishart J, et al. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. *Diabetes Obese tab* 2002;4:329-335.
62. Kenny RA. Syncope in the elderly: Diagnosis, evaluation, and treatment. *J Cardiovasc Electrophysiol* 2003;14(9 Suppl):S74-S77.
63. Shaw FE, Kenny RA. The overlap between syncope and falls in the elderly. *Postgrad Med J* 1997;73:635-639.
64. Task Force for the Diagnosis and Management of Syncope: European Society of Cardiology (ESC); European Heart Rhythm Association (EHRA); Heart Failure Association (HFA); Heart Rhythm Society (HRS), Moya A, Sutton R, Ammirati F, et al. Guidelines for the diagnosis and management of syncope (version 2009). *Eur Heart J* 2009;30:2631-2671.
65. Shanmugam N, Liew R. The implantable loop recorder - an important addition to the armamentarium in the management of unexplained syncope. *Ann Acad Med Singapore* 2012;41:115-124.